Metformin, fluvoxamine, or ivermectin for non-hospitalized COVID-19 adults in a Phase 3 trial
Metformin Cuts Long Covid Risk by 40%
This randomized controlled trial in 1323 non-hospitalized adults with SARS-CoV-2 infection evaluated metformin, fluvoxamine, or ivermectin v…
A common diabetes pill taken early in Covid infection cuts the odds of developing long-term symptoms by 40%, offering new hope for millions.
Systematic review finds no benefit of higher-dose fluvoxamine for preventing deterioration in mild-moderate COVID-19
Higher-Dose Fluvoxamine Shows No Clear Benefit for COVID-19, New Analysis Finds
This systematic review and meta-analysis evaluated higher-dose fluvoxamine (2 x 100 mg/day) versus placebo in adults with mild-to-moderate C…
This new analysis suggests that higher doses of fluvoxamine, once thought to help early COVID-19, likely don’t prevent the disease from prog…